Rating Change
Jefferies analysts initiated coverage on Artivion, Inc. (NYSE:AORT) with a rating of Buy on October 20, 2026.
Jefferies analysts initiated coverage on Artivion, Inc. (NYSE:AORT) with a rating of Buy on October 20, 2026.

At publication ·
Artivion, Inc. (NYSE:AORT) · new coverage
At a glance
Jefferies analysts initiated coverage on Artivion, Inc. (NYSE:AORT) with a rating of Buy on October 20, 2026.
Artivion, Inc. operates in the Healthcare sector. The stock currently trades at $22.92 with a market capitalization of $1.8B. The stock has declined 46.4% over the past 52 weeks.
Analyst coverage from Jefferies provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Artivion, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 20, 2026 | Jefferies | Buy | N/A |
| Aug 18, 2026 | Canaccord Genuity | Buy | N/A |
| Jul 20, 2026 | Needham | Buy | N/A |
| Jun 16, 2026 | Canaccord Genuity | Buy | N/A |
| May 08, 2026 | Citizens | Market Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View AORT Stock Page
A rating of Buy from Jefferies reflects the analyst's outlook on Artivion, Inc. (NYSE:AORT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the AORT forecast page.
Current market data
NYSE · AORT
$23.44
Up: +$0.52 · +2.27%
Live quote updated
Keep reading